TransMedics director buys 1,336 shares at $81.63

A TransMedics director increased his direct holdings through a small open-market share purchase.

Rhea-AI Filing Summary

TransMedics Group, Inc. (TMDX) director David Weill purchased 1,336 shares of common stock in an open-market or private transaction on September 11, 2026 at $81.63 per share. Following this transaction, he directly holds 16,392 shares of TransMedics common stock. No Rule 10b5-1 trading plan is reported for this purchase.

Insider Trade Summary

Net Buyer: 1,336 shares

Net Buy 1 txn

Insider Weill David

Role Director

Bought 1,336 shs ($109K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,336	$81.63	$109K

Holdings After Transaction: Common Stock — 16,392 shares (Direct)

Key Figures

Shares purchased: 1,336 shares Purchase price: $81.63 per share Shares held after transaction: 16,392 shares +1 more

4 metrics

Shares purchased 1,336 shares Common stock bought on September 11, 2026

Purchase price $81.63 per share Price for the September 11, 2026 common stock purchase

Shares held after transaction 16,392 shares Direct holdings of David Weill after the reported purchase

Net shares bought 1,336 shares Net buy across all transactions reported on this Form 4

Key Terms

open market or private transaction, Rule 10b5-1, direct ownership

3 terms

open market or private transaction market

"Purchase in open market or private transaction"

Rule 10b5-1 regulatory

"The Rule 10b5-1 checkbox is not affirmed for this filing"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

direct ownership financial

"The transaction reports the ownership type as direct"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TMDX director David Weill report?

Director David Weill reported a purchase of 1,336 TransMedics (TMDX) common shares on September 11, 2026 in an open-market or private transaction at $81.63 per share.

How many TransMedics (TMDX) shares did David Weill buy and at what price?

David Weill bought 1,336 TransMedics (TMDX) common shares at a price of $81.63 per share in a reported open-market or private transaction.

What are David Weill’s total direct holdings in TransMedics (TMDX) after this trade?

After the September 11, 2026 purchase, David Weill directly holds 16,392 shares of TransMedics (TMDX) common stock as reported in the filing.

Was David Weill’s TMDX share purchase made under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirmed, so no Rule 10b5-1 trading plan is reported for this TransMedics (TMDX) share purchase.

Is this TMDX insider transaction a buy or a sell?

The Form 4 reports a buy transaction, specifically a purchase of 1,336 shares of TransMedics (TMDX) common stock in an open-market or private transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:37 PM Accepted by SEC EDGAR 09/14/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weill David

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MASSACHUSETTS 01810

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		P		1,336	A	$81.63	16,392	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	By: /s/ Matthew S. Forsyth, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)